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Abstract
Background: Analyzing time-to-onset of adverse drug reactions from treatment exposure contributes to meeting
pharmacovigilance objectives, i.e. identification and prevention. Post-marketing data are available from reporting
systems. Times-to-onset from such databases are right-truncated because some patients who were exposed to the
drug and who will eventually develop the adverse drug reaction may do it after the time of analysis and thus are not
included in the data. Acknowledgment of the developments adapted to right-truncated data is not widespread and
these methods have never been used in pharmacovigilance. We assess the use of appropriate methods as well as the
consequences of not taking right truncation into account (naive approach) on parametric maximum likelihood
estimation of time-to-onset distribution.
Methods: Both approaches, naive or taking right truncation into account, were compared with a simulation study.
We used twelve scenarios for the exponential distribution and twenty-four for the Weibull and log-logistic
distributions. These scenarios are defined by a set of parameters: the parameters of the time-to-onset distribution, the
probability of this distribution falling within an observable values interval and the sample size. An application to
reported lymphoma after anti TNF-α treatment from the French pharmacovigilance is presented.
Results: The simulation study shows that the bias and the mean squared error might in some instances be
unacceptably large when right truncation is not considered while the truncation-based estimator shows always better
and often satisfactory performances and the gap may be large. For the real dataset, the estimated expected
time-to-onset leads to a minimum difference of 58 weeks between both approaches, which is not negligible. This
difference is obtained for the Weibull model, under which the estimated probability of this distribution falling within
an observable values interval is not far from 1.
Conclusions: It is necessary to take right truncation into account for estimating time-to-onset of adverse drug
reactions from spontaneous reporting databases.
Keywords: Pharmacovigilance, Reporting databases, Right truncation, Parametric estimation, Maximum likelihood
estimation, Bias, Simulation study
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Background
Identifying and preventing adverse drug reactions are
major objectives of pharmacovigilance. Owing to design
constraints, pre-marketing clinical trials fail to iden-
tify rare events, which lead in the last decades to an
increased focus placed on the development of post-
marketing surveillance methods [1-11]. Post-marketing
spontaneous reporting of suspected adverse drug reac-
tions has proved a valuable resource for signal detection
[12-17]. It has recently been suggested that the modeling
of the time-to-onset of adverse drug reactions could be
a useful adjunct to signal detection methods, either from
spontaneous reports [18,19] or longitudinal observational
data [20]. Timely acquiring knowledge with respect to the
time-to-onset distribution of adverse drug reactions con-
tributes to meeting pharmacovigilance objectives. Early
estimation procedures tailored to available pharmacovig-
ilance data, i.e. spontaneous reporting data, should be
sought.
The data consisting of the time-to-onset among patients
who were reported to have potentially developed an
adverse drug reaction are right-truncated. Truncation
arises because some patients who were exposed to the
drug and who will eventually develop the adverse drug
reaction may do it after the time of analysis (Figure 1).
Among patients exposed to the drug, only those who
Figure 1 Right truncation and data on time-to-onset of adverse
drug reactions from spontaneous reporting databases. Some
patients who were exposed to the drug and who will eventually
develop the adverse drug reaction may do it after the time of analysis.
Here, in these hypothetical examples, the patient on the top line is
included in the database because he experienced the adverse drug
reaction before the time of analysis, i.e. x1  t1 . The patient on the
bottom line is not included in the database because he has not yet
experienced the adverse drug reaction, i.e. x2  t2 , when data are
analyzed.
experienced adverse reactions before time of analysis are
included in the database. No information is available for
the other patients. If all the patients begin their treatment
at the same time, the data are right-truncated with a single
truncation time. If they do not all begin their treatment
at the same time, the data are right-truncated with differ-
ent truncation times. In spontaneous reporting, data are
right-truncated with different truncation times and they
require appropriate statistical methods.
This paper investigates parametric maximum likelihood
estimation of the time-to-onset distribution of adverse
drug reactions from spontaneous reporting data for dif-
ferent types of hazard functions likely to be encountered
in pharmacovigilance. Acknowledgment of the develop-
ments adapted to right-truncated data is not widespread
and these methods have never been used in phar-
macovigilance. No simulation studies are available on
the accuracy of their estimates. Furthermore, a naive
approach that does not take into account right trun-
cation features of spontaneous reports and uses classi-
cal parametric methods instead of appropriate methods
may lead to misleading estimates. We consider the two
approaches, i.e. taking or not taking right truncation
into account, and the corresponding parametric maxi-
mum likelihood estimators. Both approaches are com-
pared with a simulation study conducted to evaluate
the consequences, notably in terms of bias, of not con-
sidering right truncation on the maximum likelihood
estimates, as well as assessing the performances of the
right truncation-based estimation. We also apply these
methods to a set of 64 cases of lymphoma occurring
after anti TNF-α treatment from the French pharma-
covigilance.
Methods
Proper estimation of the time-to-onset distribution
We consider a given time of analysis and the popula-
tion of exposed patients who will eventually experience
the adverse drug reaction before they die. Let X be the
time-to-onset of the adverse drug reaction of interest in
that population and F its cumulative distribution func-
tion one is willing to estimate. Observations arising from
n reported cases are (x1, t1), (x2, t2), . . . , (xn, tn), where xi
is the time-to-onset calculated as the lag between the time
of the occurrence of the reaction and the time of initiation
of treatment, and ti is the truncation time calculated as
the lag between the time of analysis and the time of initia-
tion of treatment. Let t∗ be the maximum of the observed
truncation times. All observed data meet the condition
xi  ti.
We consider a parametric model for the time-to-onset
X, with cumulative distribution function F(x; θ) and den-
sity f (x; θ), and derive the following maximum likelihood
estimations of θ .
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When right truncation, i.e. the condition xi  ti, is
ignored, the likelihood of the sample is written as:
L1(x1, x2, . . . , xn; θ) =
n∏
i=1
f (xi; θ) ;
maximizing this likelihood yields the naive estimator of θ .
When right truncation is considered, the likelihood is
modified. Observed times-to-onset consist of n indepen-
dent realizations of random variables with respective dis-
tribution the conditional distribution of Xi given {Xi  ti},
that is with cumulative distribution function F(xi;θ)F(ti;θ) and
density
f (xi;θ)
F(ti;θ)
. The likelihood is now written as:
L2(x1, x2, . . . , xn, t1, t2, . . . , tn; θ) =
n∏
i=1
f (xi; θ)
F(ti; θ)
;
the maximum likelihood estimator from this likelihood,
θ̂TBE, is the proper estimation of θ and is called the
truncation-based estimator (TBE).
The non-parametric maximum likelihood estimation
for right-truncated data was developed and used to esti-
mate the incubation period distribution for AIDS [21,22].
However, in a non-parametric setting, one can only esti-
mate the distribution function conditional on the time to
event as being less than t∗:
F̂(x)
F(t∗)
=
∏
vj>x
(
1−
nj
Nj
)
,
where the vj’s are the m distinct values of the xi’s, i =
1, . . . , n, taken by nj =
∑n
i=1 I(Xi = vj) patients and
Nj =
∑n
i=1 I(Xi  vj  ti) for 1  j  m, I denoting the
indicator function. The unconditional distribution func-
tion is not identifiable, as F(t∗) is not known and cannot
be estimated from the data.
In a parametric framework, the unconditional dis-
tribution is completely specified by a parameter θ of
finite dimension. Maximum likelihood estimation of the
parameter of interest can be conducted with the condi-
tional distributions that describe the observations and the
unconditional distribution can be estimated secondarily
by F(x; θ̂TBE). Hence parametric maximum likelihood esti-
mation is potentially more useful than non-parametric
estimation since the unconditional distribution is of inter-
est for pharmacovigilance purposes [18,20].
Simulation study
Some adverse reactions have a very short time-to-onset,
from several minutes to several hours after the beginning
of treatment. Others occur only after several days, weeks,
months or even years of exposure. This variation depends
on numerous factors such as the pharmacokinetics of the
drug and its metabolites, or the pathophysiological mech-
anism of the effect. The multiplicity of the underlying
mechanisms results in a range of possible hazard func-
tions that can be observed in pharmacovigilance [23]. The
simplest model is given by a constant hazard function
of time; the corresponding distribution is the exponen-
tial distribution with a rate parameter λ. Effects may also
have an early or a late onset, the latter being the case
for instance, when the rate of occurrence of the adverse
reaction depends on the duration of exposure. Two distri-
bution families among others make it possible to handle
a wide range of hazard functions: the Weibull distribu-
tions and the log-logistic distributions (Table 1). Both
are defined with two scalar parameters (λ,β); λ is the
scale parameter and β is the shape parameter. The haz-
ard function for the Weibull model is increasing if β > 1,
decreasing if β < 1 and constant if β = 1 where it
reduces to the exponential distribution. The hazard func-
tion for the log-logistic model is decreasing if β < 1 and
has a single maximum if β > 1. We therefore consider
the families of the exponential, Weibull and log-logistic
distributions.
The times-to-onset were generated from these three
distributions. Two values of λ were considered for the
exponential distribution: 0.05 and 1. The same values
were used for the scale parameter λ of the Weibull and
log-logistic distributions. For the shape parameter β , the
values 0.5 and 2 were chosen. The truncation times were
uniformly distributed in [0, τ ]. Survival and truncation
times were independently generated. For a chosen value
of p, with p representing the probability of X falling within
the observable values interval [ 0, τ ], the parameter τ was
determined as P(X < τ) = p. The probability 1 − p is
also a lower bound of the actual proportion of truncated
data P(X > T), the truncation time T being randomly
generated. The probability p was chosen in {0.25, 0.50,
Table 1 Exponential, Weibull and log-logistic distributions
Distribution Exponential Weibull Log-logistic
Density f (x) = λe−λx f (x) = λβ(λx)β−1e(−(λx)
β ) f (x) = λβ(λx)
β−1
(1+(λx)β )2
Support x > 0 x > 0 x > 0
Parameter(s) λ > 0 λ > 0 λ > 0
β > 0 β > 0
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0.80}. The sample size nwas chosen in {100, 500}. For each
drawn pair (X,T), if the time-to-onset was shorter than
the truncation time, then the pair was included in the data.
If not, another pair (X,T) was generated. Pairs were gen-
erated until the sample size of observations included was
equal to n.
Parametric likelihood maximization with and without
considering right truncation were performed for each
generated sample. An iterative algorithm is necessary
to solve this optimization problem except for the naive
exponential estimation. Calculations were made with the
R [24] function maxLik from the package maxLik. For
each set of simulation parameters, 1000 replications were
run.
Application study
We analyzed 64 French cases of lymphoma that occurred
after anti TNF-α treatment using the national phar-
macovigilance database at the date of February 1,
2010 [25]. The population included patients suffering
from rheumatoid arthritis, Crohn’s disease, ankylosing
spondylitis, psoriatic arthritis, psoriasis, Sjögren’s syn-
drome, dermatomyositis, polymyositis or polyarthropathy
and exposed to one or (successively) more of the three
anti TNF-α available at the study date: etanercept, adal-
imumab and infliximab. The occurrence of a malignant
lymphoma was confirmed by histopathological analysis.
Marketing authorization was obtained in August 1999
for infliximab, in September 2002 for etanercept and in
September 2003 for adalimumab. These 64 adverse effects
occurred between July 2001 and October 2009. None
of the survival or truncation times was missing in the
database. The observed maximum truncation time was
529 weeks.
All anti TNF-agents taken together, we derived the para-
metric maximum likelihood estimates and secondarily
corresponding estimated mean times, with and without
considering right truncation, for the exponential, Weibull
and log-logistic distributions. For completeness, we also
derived the non-parametric maximum likelihood estima-
tion.
The French pharmacovigilance database is developed by
the French drug agency (Agence Nationale de Sécurité du
Médicament et des produits de santé, ANSM) and is not
publicly available. It is build up and used on an ongoing
basis by the network of regional pharmacovigilance cen-
tres, which have a direct access to the data. This set of data
has already been extracted for another study [25] with the
authorization of the ANSM and the network of regional
centres, according to the internal rule.
Results
Simulation study
For each set of simulations parameters, for both
approaches and for both parameters, the bias and the
mean squared error of the parametric maximum likeli-
hood estimator, based on the 1000 replications, were cal-
culated as well as the proportion of replications where the
estimate is larger than the true value. As the iterative algo-
rithm may fail to find a maximum, those three quantities
were actually calculated on the replications where there
was no problem ofmaximization. Themean squared error
is a measure of the dispersion of the estimator around the
true value of the parameter - the smaller the better - and
Table 2 Simulation results: estimations of bias andmean squared error for the exponential model
Naive estimator TBE
λ p n BIAS(̂λ) MSE(̂λ) BIAS(̂λ) MSE(̂λ) NPM
0.05 0.25 100 0.498 0.250 0.030 0.005 224
500 0.498 0.248 0.007 0.001 79
0.05 0.50 100 0.195 0.038 0.008 0.001 85
500 0.193 0.037 <0.001 <0.001 1
0.05 0.80 100 0.073 0.005 <0.001 <0.001 2
500 0.072 0.005 <0.001 <0.001 0
1 0.25 100 10.06 102 0.462 2.17 72
500 9.95 99 0.046 0.48 10
1 0.50 100 3.91 15.4 0.126 0.49 29
500 3.86 14.9 -0.022 0.12 0
1 0.80 100 1.45 2.16 0.004 0.11 0
500 1.45 2.11 0.004 0.02 0
The mean squared error formula is MSE(̂λ) = Var(̂λ)+ (BIAS(̂λ))2 . Calculations were made on the replications where there was no problem of maximization. In the
last column appear the number of problems of maximization for the truncation-based approach. There was no problem of maximization for the naive approach.
Abbreviations: TBE truncation-based estimator,MSEmean squared error, NPM number of maximization problems.
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is used for global comparative purposes between two esti-
mation procedures, as it incorporates both the variance
of the estimator and its bias. The proportion of repli-
cations where the estimate is larger than the true value
makes it possible to know if the estimators tend to over-
estimate or underestimate systematically the true value of
the parameter.
Bias andmean squared error
For both approaches, for all distributions and for both
parameters, the smaller is p, the larger are the bias and the
mean squared error (Tables 2, 3 and 4). This increase with
p is smaller for the parameter β than for the parameter
λ. These estimators tend to be positively biased. However,
the bias might be almost naught for the TBE. The bias and
the mean squared error of the naive estimator are always
larger than the bias and the mean squared error of the
TBE, but to a lesser extent for the parameter β . When the
sample size n increases, the bias and the mean squared
error are almost constant for the naive estimator, while
for the TBE, they decrease clearly (Tables 2, 3 and 4). The
naive estimator might be unacceptably large whatever the
value of p, whereas the TBE shows good performances
when p is equal to 0.8, and often even less according to the
distribution.
Proportion of replications where the estimator is larger than
the true value
For both approaches, for all distributions and for both
parameters, Tables 5, 6 and 7 show that the naive esti-
mator of λ appears to be almost always larger than the
theoretical value λ, and that this is not far from being true
for the naive estimator of β . This suggests that the naive
estimator of λ might be almost surely larger than the true
Table 3 Simulation results: estimations of bias andmean squared error for theWeibull model
Naive estimator TBE
λ̂ β̂ λ̂ β̂
λ β p n BIAS MSE BIAS MSE BIAS MSE BIAS MSE NPM
0.05 0.5 0.25 100 4.04 16.7 0.200 0.044 0.465 0.51 0.046 0.007 312
500 3.95 15.6 0.195 0.039 0.106 0.04 0.013 0.001 201
0.05 0.5 0.50 100 0.762 0.60 0.167 0.031 0.068 0.018 0.024 0.005 172
500 0.747 0.56 0.164 0.028 0.015 0.003 0.003 0.001 22
0.05 0.5 0.80 100 0.160 0.027 0.119 0.017 0.008 0.002 0.009 0.004 9
500 0.156 0.025 0.113 0.013 0.001 <0.001 0.001 <0.001 0
1 0.5 0.25 100 80.4 6612 0.201 0.044 8.68 183 0.046 0.007 300
500 78.9 6249 0.194 0.038 2.07 17 0.012 0.001 186
1 0.5 0.50 100 15.0 233 0.174 0.034 1.53 7.99 0.031 0.006 163
500 15.0 225 0.164 0.028 0.32 1.17 0.003 0.001 24
1 0.5 0.80 100 3.20 10.8 0.117 0.017 0.16 0.67 0.007 0.004 13
500 3.15 10.0 0.112 0.013 0.041 0.15 <0.001 <0.001 0
0.05 2 0.25 100 0.121 0.015 0.354 0.16 <0.001 0.002 0.097 0.075 8
500 0.120 0.014 0.333 0.12 -0.004 0.001 0.020 0.016 2
0.05 2 0.50 100 0.065 0.004 0.278 0.11 -0.004 <0.001 0.047 0.074 6
500 0.064 0.004 0.264 0.08 -0.002 <0.001 0.004 0.016 0
0.05 2 0.80 100 0.032 0.001 0.182 0.063 <0.001 <0.001 0.046 0.063 1
500 0.032 0.001 0.157 0.031 <0.001 <0.001 0.008 0.014 0
1 2 0.25 100 2.41 5.84 0.364 0.17 0.090 0.79 0.10 0.075 1
500 2.41 5.79 0.336 0.12 -0.082 0.38 0.02 0.015 0
1 2 0.50 100 1.29 1.68 0.283 0.12 -0.073 0.33 0.052 0.069 3
500 1.29 1.65 0.261 0.07 -0.065 0.12 -0.002 0.017 0
1 2 0.80 100 0.638 0.41 0.186 0.065 -0.024 0.086 0.045 0.064 0
500 0.636 0.40 0.154 0.030 -0.007 0.014 0.004 0.013 0
The mean squared error formula is MSE(̂λ) = Var(̂λ)+ (BIAS(̂λ))2 . Calculations were made on the replications where there was no problem of maximization. In the
last column appear the number of problems of maximization for the truncation-based approach. There was no problem of maximization for the naive approach.
Abbreviations: TBE truncation-based estimator,MSEmean squared error, NPM number of maximization problems.
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Table 4 Simulation results: estimations of bias andmean squared error for the log-logistic model
Naive estimator TBE
λ̂ β̂ λ̂ β̂
λ β p n BIAS MSE BIAS MSE BIAS MSE BIAS MSE NPM
0.05 0.5 0.25 100 6.45 44 0.384 0.16 0.258 0.25 0.041 0.008 217
500 6.33 40 0.372 0.14 0.043 0.01 0.005 0.001 52
0.05 0.5 0.50 100 1.05 1.2 0.319 0.108 0.045 0.012 0.020 0.006 22
500 1.02 1.1 0.308 0.096 0.009 0.001 0.003 0.001 0
0.05 0.5 0.80 100 0.165 0.031 0.195 0.041 0.008 0.001 0.008 0.004 0
500 0.158 0.026 0.189 0.036 0.001 <0.001 0.001 <0.001 0
1 0.5 0.25 100 129 17533 0.383 0.15 5.06 87 0.042 0.008 207
500 127 16217 0.374 0.14 1.01 6 0.008 0.001 41
1 0.5 0.50 100 21.0 467 0.317 0.106 0.93 5.0 0.019 0.006 43
500 20.5 426 0.308 0.096 0.20 0.6 0.004 0.001 0
1 0.5 0.80 100 3.31 12 0.201 0.044 0.209 0.55 0.016 0.005 0
500 3.17 10 0.190 0.037 0.037 0.09 0.002 <0.001 0
0.05 2 0.25 100 0.150 0.022 1.06 1.2 <0.001 0.001 0.08 0.085 4
500 0.149 0.022 1.04 1.1 -0.001 <0.001 0.01 0.018 0
0.05 2 0.50 100 0.079 0.006 0.932 0.94 <0.001 <0.001 0.06 0.094 5
500 0.078 0.006 0.903 0.83 <0.001 <0.001 0.01 0.017 0
0.05 2 0.80 100 0.035 0.001 0.665 0.50 <0.001 <0.001 0.03 0.078 0
500 0.035 0.001 0.649 0.43 <0.001 <0.001 0.01 0.013 0
1 2 0.25 100 2.99 9.0 1.07 1.2 0.024 0.57 0.08 0.089 0
500 2.98 8.9 1.04 1.1 -0.028 0.20 0.01 0.020 0
1 2 0.50 100 1.57 2.49 0.943 0.96 0.007 0.19 0.063 0.095 1
500 1.56 2.45 0.896 0.82 -0.013 0.04 0.004 0.018 0
1 2 0.80 100 0.702 0.50 0.668 0.50 0.004 0.042 0.045 0.072 0
500 0.693 0.48 0.648 0.43 0.004 0.007 0.015 0.013 0
The mean squared error formula is MSE(̂λ) = Var(̂λ)+ (BIAS(̂λ))2 . Calculations were made on the replications where there was no problem of maximization. In the
last column appear the number of problems of maximization for the truncation-based approach. There was no problem of maximization for the naive approach.
Abbreviations: TBE truncation-based estimator,MSEmean squared error, NPM number of maximization problems.
value of the parameter, which would be a - non desirable -
statistical feature of the naive estimator.
Application study
Table 8 presents the estimates of the parameters for the
three models and both approaches. There was no problem
of maximization. The naive estimates are always larger
than the truncation-based estimates. From the simulation
results, it might be thought that the naive estimator over-
estimates the true values of parameters λ and β , and that
the size of the bias is related to the unknown probability
p. Estimations of the parameters for the truncation-based
approach make it possible to estimate p by calculating
F(t∗ = 529; θ̂TBE). However, estimates of p are different
according to the model (Table 8). In particular, for the
Weibull model, the estimate is large (̂p = 0.98). The larger
is p̂, the closer are the naive and the truncation-based
estimates.
Figure 2 shows the non-parametric maximum like-
lihood estimation of the conditional survival function,
F̂(x)
F(529) , and the parametric maximum likelihood estima-
tion of the conditional, F(x;̂θTBE)
F(529;̂θTBE)
, and unconditional,
F(x; θ̂TBE), survival functions for the truncation-based
approach for these data. The estimations of the con-
ditional survival functions are always closer to the
non-parametric estimation than the estimations of the
unconditional survival functions. The conditional and
unconditional estimations of the Weibull survival func-
tions are almost similar because the estimate of p is about
1. This figure shows that the estimation of the conditional
Weibull survival function is closer to the non-parametric
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Table 5 Simulation results: proportion of replications
where themaximum likelihood estimator is larger than
the true value of the parameter for the exponential model
λ p n Naive estimator TBE
0.05 0.25 100 100% 61.6%
500 100% 55.3%
0.05 0.50 100 100% 55.3%
500 100% 50.4%
0.05 0.80 100 100% 51.1%
500 100% 51.7%
1 0.25 100 100% 54.8%
500 100% 50.7%
1 0.50 100 100% 53.2%
500 100% 48.0%
1 0.80 100 100% 50.0%
500 100% 51.0%
Calculations were made on the replications where there was no problem of
maximization. Abbreviations: TBE truncation-based estimator.
maximum likelihood estimation of the conditional sur-
vival function than the estimations of the conditional
exponential and conditional log-logistic survival func-
tions. Thus, Weibull could be a reasonable candidate
model to describe the data.
Figure 3 shows the parametric maximum likelihood
estimation of the unconditional survival function for
both approaches. The distance between both survivals,
naive and truncation-based, decreases with the estimated
probability p̂ (in the order: exponential, log-logistic and
Weibull). Furthermore, the survival functions from the
truncation-based estimates are always above the survival
functions from the naive estimates, which is consistent
with the naive estimator overestimating the true val-
ues of the parameters λ and β . Even for the Weibull
model, i.e. the model with the largest p̂, the estimated
expected time-to-onset would be 135 weeks with the
naive approach and 193 weeks with the truncation-based
estimates, which corresponds to a markedly large gap
(Table 8). For completeness, we also calculated the 95%
simple bootstrap confidence intervals of the expected
time (BCa method) [26,27] based on 5000 bootstrap sam-
ples, for the truncation-based approach. They do not
include the naive estimated mean time, whatever the fit-
ted model, and even though these confidence intervals are
extremely wide.
Discussion and conclusions
In drug safety assessment, the temporal relationship
between drug administration and time-to-onset is of
utmost relevance. A better understanding of the under-
lying mechanism of the occurrence of an adverse effect
Table 6 Simulation results: proportion of replications
where themaximum likelihood estimator is larger than
the true value of the parameter for theWeibull model
Naive estimator TBE
λ β p n λ̂ > λ β̂ > β λ̂ > λ β̂ > β
0.05 0.5 0.25 100 100% 100% 81.4% 71.9%
500 100% 100% 64.6% 64.5%
0.05 0.5 0.50 100 100% 100% 63.3% 60.1%
500 100% 100% 53.4% 51.0%
0.05 0.5 0.80 100 100% 99.6% 52.0% 53.3%
500 100% 100% 48.6% 51.6%
1 0.5 0.25 100 100% 100% 79.3% 76.0%
500 100% 100% 62.0% 61.2%
1 0.5 0.50 100 100% 100% 65.9% 64.6%
500 100% 100% 53.8% 51.8%
1 0.5 0.80 100 100% 99.5% 52.7% 52.2%
500 100% 100% 51.9% 50.6%
0.05 2 0.25 100 100% 98.1% 52.1% 61.6%
500 100% 100% 52.2% 53.7%
0.05 2 0.50 100 100% 94.2% 51.6% 53.3%
500 100% 100% 50.6% 51.0%
0.05 2 0.80 100 100% 85.4% 56.1% 55.8%
500 100% 97.9% 52.2% 49.6%
1 2 0.25 100 100% 98.2% 56.2% 62.5%
500 100% 99.9% 50.1% 54.8%
1 2 0.50 100 100% 94.3% 53.9% 54.2%
500 100% 99.9% 47.1% 48.1%
1 2 0.80 100 100% 85.3% 54.1% 54.2%
500 100% 97.9% 52.7% 52.2%
Calculations were made on the replications where there was no problem of
maximization. Abbreviations: TBE truncation-based estimator.
is crucial, as it could allow the identification of par-
ticular groups of patients at risk and of particular risk
time-windows in the course of a treatment and lead to
preventing or diagnosing earlier the occurrence of adverse
reactions. In this framework, the time-to-onset of an
adverse drug reaction constitutes an essential feature to be
analyzed. Its accurate estimation and modeling could help
in understanding the mechanism of a drug’s action.
As rare adverse effects are not generally identified by
cohort studies of exposed patients but from spontaneous
reporting systems, we investigated with a simulation study
the accuracy of estimates that can be obtained from these
data in a parametric framework. As one can only estimate
a conditional distribution function in a non-parametric
setting, the non-parametric maximum likelihood estima-
tor is of rather little interest for pharmacovigilance peo-
ple. For a finite sample size, the simulations show that,
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Table 7 Simulation results: proportion of replications
where themaximum likelihood estimator is larger than
the true value of the parameter for the log-logistic model
Naive estimator TBE
λ β p n λ̂ > λ β̂ > β λ̂ > λ β̂ > β
0.05 0.5 0.25 100 100% 100% 67.2% 67.7%
500 100% 100% 53.6% 52.0%
0.05 0.5 0.50 100 100% 100% 55.4% 57.5%
500 100% 100% 51.1% 52.0%
0.05 0.5 0.80 100 100% 100% 51.1% 53.2%
500 100% 100% 50.8% 51.5%
1 0.5 0.25 100 100% 100% 67.7% 66.1%
500 100% 100% 55.9% 56.1%
1 0.5 0.50 100 100% 100% 54.9% 57.2%
500 100% 100% 53.4% 53.4%
1 0.5 0.80 100 100% 100% 55.1% 56.5%
500 100% 100% 51.9% 52.0%
0.05 2 0.25 100 100% 100% 53.2% 55.9%
500 100% 100% 51.8% 51.8%
0.05 2 0.50 100 100% 100% 55.0% 54.2%
500 100% 100% 53.3% 52.2%
0.05 2 0.80 100 100% 100% 50.3% 51.5%
500 100% 100% 53.9% 54.4%
1 2 0.25 100 100% 100% 52.7% 56.1%
500 100% 100% 53.3% 51.0%
1 2 0.50 100 100% 100% 54.3% 56.4%
500 100% 100% 50.1% 49.5%
1 2 0.80 100 100% 100% 52.0% 53.7%
500 100% 100% 52.9% 55.0%
Calculations were made on the replications where there was no problem of
maximization. Abbreviations: TBE truncation-based estimator.
whatever the approach, naive or truncation-based, the
parametric maximum likelihood estimator may be pos-
itively biased and that this bias and the corresponding
mean squared error increase when the theoretical proba-
bility p for the time-to-onset to fall within the observable
values interval decreases. However, for a fixed value of
p, the bias and the mean squared error are always larger
when the right truncation is not considered than when
it is, and the gap may be large. In addition, bias and
mean squared error might in some instances (Weibull,
log-logistic) be unacceptably large for the naive approach,
even for a large value of p, while with a probability p of
0.8, or sometime even less, the TBE shows good perfor-
mances. Asymptotically, the naive estimator may not be
unbiased because the bias and the mean squared error
seem to be constant with the sample size and the max-
imization is based on a misleading likelihood, while the
bias and the mean squared error for the TBE decrease as
the sample size increases. Therefore, even if the sample
size is large, the gap between both estimators does not
disappear and the truncation-based approach should be
used.
The probability p plays an important role in the esti-
mation of the distribution of the time-to-onset of adverse
reaction for right-truncated data. Knowledge exists on a
range of possible pharmacological mechanisms. It is thus
possible to get a rough idea of the fraction of potentially
missed cases (the adverse reactions of treated patients that
have yet to occur) and then to decide on the relevance
of the time of analysis. Spontaneous reports result from
three processes: the occurrence case process, its diag-
nosis and the reporting process. It is well known that
under-reporting is widespread, even for serious events. In
addition, factors of under-reporting include the serious-
ness of the effect, the age of the patient and the novelty
of the effect, but also time-related variables such as the
length of marketing or the time since exposure [28-33]. In
the approach proposed here, it is assumed that the under-
reporting is uniform. Such a hypothesis might not always
be acceptable. However, with long-term effects such as
lymphoma and a homogeneous observation period within
the marketing life of the product, non-stationarity of
reporting is unlikely.
Problems of maximization may arise when right trunca-
tion is taken into account. The smaller is p, the more the
iterative algorithm is likely to fail. Some papers mentioned
the existence of a problem in the parametric likelihood
Table 8 Parameter estimation and estimatedmean time-to-onset for 64 cases of lymphoma that occurred after anti
TNF-α treatment
Naive estimator TBE
Distribution λ̂ β̂ Expectation (weeks) λ̂ β̂ p̂ Expectation (weeks)
Exponential 0.00739 - 135 0.00172 - 0.60 581 [264,7528]∗
Weibull 0.00666 1.55 135 0.00468 1.49 0.98 193 [150,432]∗
Log-logistic 0.00890 2.06 171 0.00408 1.53 0.76 567 [207,1.8×1012]∗
∗95% confidence intervals calculated using BCa simple bootstrap method based on 5000 replicates.
p̂ = F(t∗ = 529; (̂λTBE , β̂TBE)).
Abbreviations: TBE truncation-based estimator.
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Figure 2 Right truncation-based estimations of time-to-onset of lymphoma that occurred after anti TNF-α treatment. Data include 64
cases. Three models are fitted: exponential, Weibull and log-logistic. Estimations of the conditional survival function (C), estimations of the
unconditional survival function (U) and the non-parametric maximum likelihood estimation of the survival function (NPMLE) are displayed.
Figure 3 Naive and right truncation-based estimations of time-to-onset of lymphoma that occurred after anti TNF-α treatment. Data
include 64 cases. Three models are fitted: exponential, Weibull and log-logistic. Estimations of the unconditional survival function for the naive
approach (Naive) and for the truncation-based approach (TBE) are displayed.
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maximization and explained that, because of right trunca-
tion, the likelihood may be flat and the maximum may be
difficult to find [21,34-36].
For the 64 cases of lymphoma after anti TNF-α treat-
ment, there was no problem of convergence of the iterative
algorithm. Both estimates, naive and truncation-based,
were available for each fitted model. From the truncation-
based estimates, it is possible to estimate p. Here it
ranges from 0.98 (Weibull) to 0.60 (exponential). Since
this probability is unknown, the non-parametric maxi-
mum likelihood estimation estimates only the distribu-
tion function conditional on the time-to-event being less
than the maximum observed truncation time. However,
although conditional, the non-parametric estimate is a
reference that provides an idea of how the data fit a given
model. We followed the graphical procedure for check-
ing goodness-of-fit for right-truncated data suggested
by Lawless (2003) that is based on the non-parametric
maximum likelihood estimator and consists in plotting
the conditional fitted parametric survivals together with
the non-parametric estimation [36]. Here, the condi-
tional Weibull survival function seems the closest to the
non-parametric estimation. This finding underlines the
interest for developing goodness-of-fit tests adapted to
right-truncated data. While only three families of distri-
butions were considered for the present simulation study,
other families could be explored such as the gamma or
the log-normal families or mixture models. For instance,
in more complex situations, the treatment might be a
combination of drugs, each of them inducing the effect
but in a different time window. In that case, the hazard
function may vary several times and a family of more
complex distributions could be of greater interest. Addi-
tionally, we chose to consider the truncation times as
deterministic, which is equivalent to working on condi-
tional distributions for the likelihood. However, another
possible approach is to consider the truncation time as
a random variable and to study the random pair (X,T)
where X is the survival time and T is the truncation time
[37-39].
Finally, improvement of time-to-onset distribution
assessment could make it possible to compare two drug
profiles or more generally to assess risk factors with
regression models.
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